50.75
03-May-24 10:29:54
15 minutes delayed
Stocks
+0.55
+1.10%
Today's range
50.15 - 51.20
ISIN
IT0003828271
Source
Cboe
RECORDATI: POSITIVE RESULTS FROM THE PHASE III LINC 4 STUDY PRESENTED AT THE ENDOCRINE SOCIETY’S ANNUAL MEETING REINFORCE THE EFFICACY AND SAFETY OF ISTURISA® (OSILODROSTAT) IN CUSHING’S DISEASE
23 Mar 2021 03:00:34 By Nasdaq GlobeNewswire
RECORDATI: PRELIMINARY 2020 RESULTS CONFIRM CONTINUED GROWTH OF OPERATING INCOME AND NET INCOME. EBITDA +4.7% AND ADJUSTED NET INCOME +7.3%.
22 Feb 2021 06:20:07 By Nasdaq GlobeNewswire
RECORDATI: LICENSE OBTAINED FOR THE COMMERCIALIZATION OF ELIGARD IN EUROPE AND OTHER COUNTRIES
29 Jan 2021 11:11:16 By Nasdaq GlobeNewswire